Search research articles
Contact Us
Filters
Showing results (71-80 of 124) with videos related to
Page
of 13
Sort By:
Nature
|
September 22, 1988
Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein
V K Chaudhary, T Mizukami, T R Fuerst, et al.
Scientific Reports
|
April 20, 2019
Common patterns of gene regulation associated with Cesarean section and the development of islet autoimmunity - indications of immune cell activation
M Laimighofer, R Lickert, R Fuerst, et al.
Journal of Chromatography. B, Biomedical Applications
|
October 11, 1996
Purification and characterization of a recombinant hepatitis E protein vaccine candidate by liquid chromatography-mass spectrometry
C P McAtee, Y Zhang, P O Yarbough, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 15, 1991
Specific lysis of human immunodeficiency virus type 1-infected cells by a HLA-A3.1-restricted CD8+ cytotoxic T-lymphocyte clone that recognizes a conserved peptide sequence within the gp41 subunit of the envelope protein
K Takahashi, L C Dai, T R Fuerst, et al.
Virology
|
December 31, 1997
In vitro infection and replication of hepatitis E virus in primary cynomolgus macaque hepatocytes
A W Tam, R White, P O Yarbough, et al.
New Biotechnology
|
December 21, 2023
Site-directed neutralizing antibodies targeting structural sites on SARS-CoV-2 spike protein
Xiaofeng Li, Liudmila Kulakova, Kezzia Jones, et al.
The Journal of Biological Chemistry
|
March 5, 2015
Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody
Yili Li, Brian G Pierce, Qian Wang, et al.
Brain : a Journal of Neurology
|
June 27, 2000
Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A
K M Krajewski, R A Lewis, D R Fuerst, et al.
Vaccine
|
June 1, 1990
Defining minimal requirements for antibody production to peptide antigens
G Goodman-Snitkoff, L E Eisele, E P Heimer, et al.
Clinical and Vaccine Immunology : CVI
|
August 30, 2013
Increasing the potency of an alhydrogel-formulated anthrax vaccine by minimizing antigen-adjuvant interactions
Allan Watkinson, Andrei Soliakov, Ashok Ganesan, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 124) with videos related to
Sort By:
Page
of 13
Nature
|
September 22, 1988
Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein
V K Chaudhary, T Mizukami, T R Fuerst, et al.
Scientific Reports
|
April 20, 2019
Common patterns of gene regulation associated with Cesarean section and the development of islet autoimmunity - indications of immune cell activation
M Laimighofer, R Lickert, R Fuerst, et al.
Journal of Chromatography. B, Biomedical Applications
|
October 11, 1996
Purification and characterization of a recombinant hepatitis E protein vaccine candidate by liquid chromatography-mass spectrometry
C P McAtee, Y Zhang, P O Yarbough, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 15, 1991
Specific lysis of human immunodeficiency virus type 1-infected cells by a HLA-A3.1-restricted CD8+ cytotoxic T-lymphocyte clone that recognizes a conserved peptide sequence within the gp41 subunit of the envelope protein
K Takahashi, L C Dai, T R Fuerst, et al.
Virology
|
December 31, 1997
In vitro infection and replication of hepatitis E virus in primary cynomolgus macaque hepatocytes
A W Tam, R White, P O Yarbough, et al.
New Biotechnology
|
December 21, 2023
Site-directed neutralizing antibodies targeting structural sites on SARS-CoV-2 spike protein
Xiaofeng Li, Liudmila Kulakova, Kezzia Jones, et al.
The Journal of Biological Chemistry
|
March 5, 2015
Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody
Yili Li, Brian G Pierce, Qian Wang, et al.
Brain : a Journal of Neurology
|
June 27, 2000
Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A
K M Krajewski, R A Lewis, D R Fuerst, et al.
Vaccine
|
June 1, 1990
Defining minimal requirements for antibody production to peptide antigens
G Goodman-Snitkoff, L E Eisele, E P Heimer, et al.
Clinical and Vaccine Immunology : CVI
|
August 30, 2013
Increasing the potency of an alhydrogel-formulated anthrax vaccine by minimizing antigen-adjuvant interactions
Allan Watkinson, Andrei Soliakov, Ashok Ganesan, et al.
Page
of 13